LPCN News and Press, Lipocine Inc. From 07/27/23

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the ...

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by lev...

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023...

2023-05-16 09:47:57 ET Lipocine ( NASDAQ: LPCN ) stock fell ~6% on Tuesday after reporting data from a pilot pharmacokinetic (PK) bridge study of LPCN 1154 (oral brexanolone), versus IV brexanolone for postpartum depression (PPD). The study enrolled 12 people and e...

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression PR Newswire Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establis...

2023-05-11 06:49:36 ET Lipocine press release ( NASDAQ: LPCN ): Q1 GAAP EPS of -$0.04 misses by $0.01 . For further details see: Lipocine GAAP EPS of -$0.04 misses by $0.01

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 PR Newswire SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by ...

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 PR Newswire LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 ...

2023-03-10 09:31:06 ET Lipocine press release ( NASDAQ: LPCN ): FY GAAP EPS of -$0.13 in-line. Revenue of $0.5M (-96.9% Y/Y) misses by $0.91M . As of December 31, 2022, Lipocine had $32.5 million of unrestricted cash, cash equivalents and marketable investment...

Lipocine Announces Financial Results for the Year Ended December 31, 2022 PR Newswire SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leverag...